Percutaneous 17 beta-estradiol in treatment of cancer of prostate.
A natural estrogen, 17 beta-estradiol, was given percutaneously to 21 patients with untreated cancer of the prostate. The follow-up lasted three to six months, and the results of the survey were encouraging. The hormonal controls showed good plasma diffusion of estrogen, a significant drop in plasma testosterone, and decreased hypophyseal secretion as shown by lower follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels. Triglycerides and very low density lipoproteins (VLDL) which are considered to be good indicators of cardiovascular risk were unchanged.
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy; D013196:Dihydrotestosterone / Q000097:blood; D004958:Estradiol / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004970:Estrone / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008079:Lipoproteins, VLDL / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood
D008079:Lipoproteins, VLDL; D014280:Triglycerides; D013196:Dihydrotestosterone; D004970:Estrone; D013739:Testosterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone